Taiho Pharmaceutical and Phost in Therapeutics Announce Licence Agreement on GnT-V Inhibitor PhOx430

Taiho Pharmaceutical and Phost’in Therapeutics have entered into an option and licence agreement that outlines their collaboration regarding the development and commercialisation of a novel compound named PhOx430.

Under the terms of this agreement, Taiho Pharmaceutical has acquired option rights to in-licence PhOx430 and other undisclosed compounds. In exchange for these rights, Taiho Pharmaceutical has made an upfront payment to Phost’in. The primary focus of this partnership is to exclusively develop and market these compounds in Japan and specific Asian territories (excluding China).

The strategic collaboration between Taiho Pharmaceutical and Phost’in aims to advance the development of innovative and valuable pharmaceuticals to address unmet medical needs.

PhOx430 is currently in the Phase I/II stages of clinical evaluation in Europe as part of the PhAST trial. This trial is assessing its efficacy and safety in patients with advanced solid tumours.

PhOx430 is the flagship programme from Phost’in's Phost’ScreenTM platform, which leverages proprietary chemical libraries and advanced screening technologies to identify and develop selective N-glycosylation inhibitors. These inhibitors have the potential to be utilised in treating a range of serious conditions, including cancer and other immunoinflammatory diseases.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!